Trump’s Pharma Threats Take Tariffs Into Uncharted Territory

Atli Stannard’s commentary was included in a Bloomberg article examining the effects of proposed pharma tariffs by the Trump administration.

Atli notes that while tariffs will affect U.S. consumers and companies as well as those further afield, some businesses may be either unable or unwilling to dismantle the existing supply chain.

“Either there is no way to change it in the immediate term or it just doesn’t make sense financially to change it fundamentally,” he said. “If you invested millions in building a biosecure plant in Europe and you only need one such plant in the world, it may not make sense to replicate it in the U.S.”